Modalis Therapeutics Corporation Stock: price and insider trades · Japan

This page follows insider dealings at Modalis Therapeutics Corporation as filed with EDINET (Japan FSA), a company from the Health Care sector. Over the twelve months to 10 November 2026, 93 filings were filed, from 3 insiders.

The flow runs one way only: 64 sales worth €74k, from 2 insiders, and no purchase. The totals do not cover 56 filings with an undisclosed amount. Evo Fund filed the largest sale, €50k, on 28 September 2026, which represents 0.26% of the company's market value.

Between a trade and the moment it shows up on EDINET (Japan FSA), the median delay is 18 days. This delay matters because a trade only becomes useful information once it is public. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

For context, the typical company on the same exchange (median of 3,233 companies) published 3 filings over the same period, against 93 filings here. The full history, which starts in 2022, counts 117 purchases against 242 sales.

Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and Vetoquinol SA. Every figure here comes from the filings published by EDINET (Japan FSA) and describes the past, not future prices; it is not investment advice.